Clinical associations of the AC-16 tropomyosin-like cytoplasmic ANA pattern with rheumatoid arthritis and malignancy in an ANA-tested population
Abstract
Purpose: The aim of this study was to assess the clinical correlations of AC-16 tropomyosin-like cytoplasmic pattern positivity in a routine ANA-tested population.
Meaterial and Methods: This retrospective case-control study had 310 patients, including 155 AC-16-positive individuals and 155 AC-16-negative controls. Demographic and clinical factors were analyzed across groups. Logistic regression analyses were conducted to determine both unadjusted and age- and sex-adjusted correlations between AC-16 positivity and specific clinical outcomes. A disease-matched subgroup analysis was also performed in patients with rheumatoid arthritis.
Results: Patients positive for AC-16 demonstrated a higher prevalence of autoimmune diseases, rheumatoid arthritis, and malignancies in comparison to the control group. In unadjusted analyses, AC-16 positivity correlated with autoimmune disease (OR 1.64, 95% CI 1.03–2.62), rheumatoid arthritis (OR 2.53, 95% CI 1.13–5.67), and malignancy (OR 2.37, 95% CI 1.07–5.24). ROC analysis indicated modest discrimination for rheumatoid arthritis (AUC = 0.66) and any autoimmune disease (AUC = 0.63), while the discriminatory performance for malignancy was limited (AUC = 0.61). A subgroup analysis of rheumatoid arthritis patients revealed similar demographic and laboratory characteristics between the AC-16-positive and pattern-negative groups.
Conclusion: AC-16 tropomyosin-like cytoplasmic pattern positivity is independently associated with autoimmune disease, particularly rheumatoid arthritis, as well as malignancy, whereas ANA-IIF titer levels do not appear to offer further clinical significance.
Keywords
AC-16, cytoplasmic pattern, antinuclear antibodies, autoimmunity, indirect immunofluorescence
Ethical Statement
This study was approved by the Ankara Bilkent City Hospital and Institute review board (Date: 12.07.2023, Decision No: E2-23-4480). The study was conducted in compliance with the Declaration of Helsinki
References
- Smillie LB. Structure and functions of tropomyosins from muscle and non-muscle sources. Trends Biochem Sci. 1979;4:151-5.
- Kaşifoğlu N, Yaşar Bilge NŞ, Kaşifoğlu T. The anti-cytoplasmic and anti-mitotic autoantibodies; are these antibodies associated with diseases? Osmangazi Tıp Dergisi. 2022;44:851-61.
- Ebert EC, Geng X, Lin J, Das KM. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell Immunol. 2006;244:43-9.
- Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Behçet’s syndrome. Eur J Immunol. 2002;32:356-65.
- Meng Y, Huang K, Shi M, Huo Y, Han L, Liu B et al. Research advances in the role of the tropomyosin family in cancer. Int J Mol Sci. 2023;24:13295.
- Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100-23.
- Ebert EC, Geng X, Bajpai M, Pan Z, Tatar E, Das KM. Antibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis. Am J Gastroenterol. 2009;104:2996-3003.
- Fujita A, Kuroda S, Tada H, Hidaka Y, Kimura M, Takeoka K et al. Enzyme-linked immunosorbent assay for anti-tropomyosin antibodies and its clinical application to various heart diseases. Clin Chim Acta. 2000;299:179-92.
- Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY et al. Alpha tropomyosin as a self-antigen in patients with Behçet’s disease. Clin Exp Immunol. 2005;140:368-75.
- Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 1988;140:1490-5.
